pd l1 t hank Search Results


pd l1 t hank  (ImmunityBio Inc)
86
ImmunityBio Inc pd l1 t hank
Pd L1 T Hank, supplied by ImmunityBio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd l1 t hank/product/ImmunityBio Inc
Average 86 stars, based on 1 article reviews
pd l1 t hank - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier
pd l1 t hank cells  (ImmunityBio Inc)
86
ImmunityBio Inc pd l1 t hank cells
Fulvestrant sensitization of ER− breast cancer cells increases killing by NK cells treated with N-803 and PD-L1 t-haNKs. (A) 24-hour pretreatment of NK cells with 50 nM N-803 synergizes with 24-hour pretreatment of ER− breast cancer cells with 50 mM selective estrogen receptor degrading drug fulvestrant to increase NK cell–mediated killing over N-803 pretreatment alone. (B) Flow staining demonstrates that 24-hour pretreatment of ER− cells with 50 mM fulvestrant increases PD-L1 protein expression in SUM149 but not BT549 cells (insets). 24-hour pretreatment of ER− cells with 50 mM fulvestrant increases PD-L1 <t>t-haNK-mediated</t> cell killing. Flow cytometry analysis was repeated >3 times with similar results. 24-hour cell lysis was evaluated through 111 IN-release assay at 20:1 E:T ratio. *p<0.05.
Pd L1 T Hank Cells, supplied by ImmunityBio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd l1 t hank cells/product/ImmunityBio Inc
Average 86 stars, based on 1 article reviews
pd l1 t hank cells - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

Image Search Results


Fulvestrant sensitization of ER− breast cancer cells increases killing by NK cells treated with N-803 and PD-L1 t-haNKs. (A) 24-hour pretreatment of NK cells with 50 nM N-803 synergizes with 24-hour pretreatment of ER− breast cancer cells with 50 mM selective estrogen receptor degrading drug fulvestrant to increase NK cell–mediated killing over N-803 pretreatment alone. (B) Flow staining demonstrates that 24-hour pretreatment of ER− cells with 50 mM fulvestrant increases PD-L1 protein expression in SUM149 but not BT549 cells (insets). 24-hour pretreatment of ER− cells with 50 mM fulvestrant increases PD-L1 t-haNK-mediated cell killing. Flow cytometry analysis was repeated >3 times with similar results. 24-hour cell lysis was evaluated through 111 IN-release assay at 20:1 E:T ratio. *p<0.05.

Journal: Journal for Immunotherapy of Cancer

Article Title: Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing

doi: 10.1136/jitc-2020-002258

Figure Lengend Snippet: Fulvestrant sensitization of ER− breast cancer cells increases killing by NK cells treated with N-803 and PD-L1 t-haNKs. (A) 24-hour pretreatment of NK cells with 50 nM N-803 synergizes with 24-hour pretreatment of ER− breast cancer cells with 50 mM selective estrogen receptor degrading drug fulvestrant to increase NK cell–mediated killing over N-803 pretreatment alone. (B) Flow staining demonstrates that 24-hour pretreatment of ER− cells with 50 mM fulvestrant increases PD-L1 protein expression in SUM149 but not BT549 cells (insets). 24-hour pretreatment of ER− cells with 50 mM fulvestrant increases PD-L1 t-haNK-mediated cell killing. Flow cytometry analysis was repeated >3 times with similar results. 24-hour cell lysis was evaluated through 111 IN-release assay at 20:1 E:T ratio. *p<0.05.

Article Snippet: PD-L1 t-haNK cells were provided by ImmunityBio through a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), National Institutes of Health (NIH).

Techniques: Staining, Expressing, Flow Cytometry, Lysis, Release Assay